z-logo
open-access-imgOpen Access
Real-life efficacy and safety of biosimilar adalimumab (ZRC-3197) in patients with plaque psoriasis: A tertiary care center experience
Author(s) -
Ajay Chopra,
Debdeep Mitra,
Reetu Agarwal,
Neerja Saraswat,
Pooja Chemburkar,
Loknandini Sharma
Publication year - 2020
Publication title -
indian dermatology online journal
Language(s) - English
Resource type - Journals
eISSN - 2249-5673
pISSN - 2229-5178
DOI - 10.4103/idoj.idoj_120_19
Subject(s) - medicine , adalimumab , dermatology life quality index , psoriasis , tolerability , psoriasis area and severity index , biosimilar , plaque psoriasis , adverse effect , discontinuation , dermatology , quality of life (healthcare) , rheumatoid arthritis , nursing
Adalimumab is proven to be safe and effective in treating plaque psoriasis. A biosimilar adalimumab (ZRC-3197; Exemptia™) - approved by Indian Regulators in 2014 - is a 'fingerprint match' of the reference adalimumab in terms of purity, potency, safety, and clinical efficacy. While reference adalimumab remains unavailable, this biosimilar adalimumab (bADA) serves as an accessible, cost-effective option for Indian patients. This is a first-hand, prospective, real-life data on the clinical use of bADA in Indian patients with plaque psoriasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here